V ascular endothelial growth factor is important in several angiogenic eye diseases, including AMD, 1,2 diabetic retinopathy, 3, 4 retinal vein occlusion, 3 and retinopathy of prematurity (ROP). 5, 6 We previously found that overactivation of VEGF receptor 2 (VEGFR2) led to disordered developmental angiogenesis 7 in a similar pattern as seen in intravitreal neovascularization (IVNV) in severe ROP. 8 Broad inhibition of VEGF with an intravitreal neutralizing antibody reduced IVNV in a rat model of ROP, but also reduced pup growth and serum VEGF levels. 9 To target pathologic effects of VEGFA without affecting physiologic ones, we localized VEGFA splice variant mRNAs to cellular retinaldehyde-binding protein (CRALBP)-labeled Müller cells, RPE, and cells in the ganglion cell layer in the retina of a rat model of ROP at a time point when total retinal VEGFA expression was significantly increased compared with room air-raised pups. 10 We created lentivectors that used CD44 promoters and efficiently drove VEGFA shRNA specifically in Müller cells when delivered into the subretinal space. 11, 12 In the short-term, IVNV was inhibited without affecting serum VEGFA, pup growth, or retinal apoptosis. 12 However, Müller cells also depend on VEGFA for survival 13 and this strategy may potentially have adverse effects. Therefore, in this study, we created lentivectors with CD44 promoters that specifically targeted Müller cell-VEGF 164 , which leads to pathologic angiogenesis 14, 15 and which we found to be the most prevalent splice variant in the ROP model. 10 We tested the hypothesis that the lentivector shRNA to rat VEGF 164 knockdown of VEGFA or control and also tested efficacy and retinal cell survival at a later time point in the ROP model. We found that targeted lentivector delivery of shRNAs to VEGFA or VEGF 164 reduced IVNV, but that shRNA to VEGF 164 maintained long-term inhibition of IVNV and limited cell death compared with shRNA to VEGFA.
METHODS
Rat Model of ROP (Rat 50/10 OIR Model)
All animal care was in accordance with the Use of Laboratory Animals and the ARVO Statement for the Use of Animals in Ophthalmology and Vision Research and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Utah. In the well-described rat oxygen-induced retinopathy (OIR) model (rat model of ROP), 16, 17 SpragueDawley (Charles River Laboratories, Inc., Wilmington, MA) dams and pups are placed into a dual channel/dual gas controller (OxyCycler; BioSpherix, Ltd., Lacona, NY) within 6 hours of birth, where oxygen is cycled between 50% and 10% every 24 hours. At postnatal day (P)14, litters were placed into room air until P18 or P25. Litter size was maintained at 12 to 16 pups. Pup weight was obtained at P8, P18, and P25. Pups were euthanized by intraperitoneal injection (IP) of ketamine (60 mg/kg) and xylazine (18 mg/kg) followed by IP pentobarbital (80 mg/kg). For all pups, one eye was processed for flatmount analysis and the fellow eye for protein or immunohistochemistry (IHC).
Construction of Lentivector-Driven shRNA
Short hairpin RNAs targeting rat VEGFA (NM_031836, VEG-FA.shRNA); rat VEGF 164 (AF260425, VEGF164.shRNA); or nonmammalian gene luciferase (M15077, luciferase.shRNA) were developed. shRNAs were embedded within a microRNA (miR-30) context as an efficient method to knock down a gene. 18, 19 The shRNA-microRNA30 was each cloned into a lentiviral transfer vector driven by a CD44 promoter specific to Müller cells (pFmCD44.1GW) and with multicistronic cotranscription of green fluorescent protein (GFP) 20 or red fluorescent protein (RFP). 11 The VEGFA.shRNAs were previously developed and tested for off-target effects and efficiency. 12 Here, we describe methods for lentivectors with VEGF164.shRNAs. Knockdown and off-target efficiency was tested in rat Müller cells (rMC-1; line provided by Vijay Sarthy, Northwestern University, Evanston, IL) and VEGF 120 and VEGF 164 HEK reporter cell lines, 12 with the goal to choose shRNAs with better knockdown efficiency in VEGF 164 but not VEGF 120 .
Cell Culture and Assay for In Vitro-Knockdown Efficiency
Rat Müller cells, VEGF 120 , and VEGF 164 HEK reporter cell lines were maintained in DMEM/high glucose (Gibco/Life Technologies, Grand Island, NY) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Both VEGF 120 and VEGF 164 HEK reporter cell lines were transfected with plasmid DNA-pFmCD44.1GW containing VEGF164.shRNA-1 or VEGF164.shRNA-2 expressed with RFP or an empty vector without shRNA as control. Forty-eight hours after transfection, the knockdown efficiency of VEGF164.shRNAs was determined by flow cytometry of GFP fluorescence in RFP positive cells. Silencing was calculated as a percentage of GFP to control vector transfected-cells. The shRNA with better knockdown efficiency in VEGF 164 but not VEGF 120 was chosen for all following experiments and designated VEGF164.shRNA.
rMC-1 cells in 6-well plates (Corning, Inc., Corning, NY) with 80% confluence were infected with lentivirus (5.0 3 10 6 viral particles/mL) containing VEGFA.shRNA, VEGF164.shRNA, luciferase.shRNA, or vehicle without viral infection. After 48 hours, cells were extracted and real-time PCR was performed. Each condition was performed in triplicate.
Subretinal Injection
At the beginning of P8 (50% oxygen cycle), pups were anesthetized by IP ketamine (20 mg/kg) and xylazine (2.5 mg/ kg). Subretinal injections were performed by creating an initial opening beneath the limbus with a 30-gauge needle. One lL of 1 3 10 9 viral particles/mL (VP/mL) of VEGFA.shRNA, VEGF164.shRNA, or control luciferase.shRNA was delivered into the subretinal space using a 33-gauge needle attached to a syringe (Hamilton Company, Reno, NY). In some pups, 1 lL of subretinal PBS was used as an additional control. The created retinal detachments resolved within 24 hours. The same virus and dose were used in each eye of the same pup. Attempts were made to represent all lentivector types in each litter and to inject the same number of pups with each lentivector preparation in each litter. Pups weighing less than 7 g were not used and all pups analyzed were within 62 g of mean pup weight based on overall growth chart. 21, 22 In Vivo Retinal Imaging
Pupil dilation was achieved with tropicamide (1% solution; Bausch & Lomb Pharmaceuticals, Inc., Rochester, NY). Genteal gel (Novartis Pharmaceuticals Corp., East Hanover, NJ) was the coupling agent for retinal imaging with a commercial applanation imaging system (Micron III; Phoenix Research Laboratories, Inc., Pleasanton, CA) and multiple camera recording software (StreamPix 5; Norpix, Inc., Montreal, Quebec, Canada). Both GFP and bright field were used for imaging.
Retinal Flatmount Preparation, Imaging, and Analysis
After euthanasia, eyes were enucleated, pierced through the cornea with a 30-gauge needle, placed into freshly made 4% paraformaldehyde (PFA) containing 10 mM sodium orthovanadate for 2 hours on ice, and then transferred to PBS. Corneas, lenses, and vitreous were removed, and retinas were dissected from the RPE/choroid/sclera. Retinal flatmounts were labeled using 5 lg/mL AlexaFluor 568 conjugated isolectin GS-IB4 from Griffonia simplicifolia (Bandeiraea; Molecular Probes, Eugene, OR) and imaged using an inverted fluorescence microscope (Olympus IX81; Olympus Corp., Tokyo, Japan). 12 Whole retinal flatmount images were stitched using the scan-slide stitching function of imaging software (Metamorph version 7.0; Molecular Devices, Inc., Sunnyvale, CA). The avascular retina (AVA) and IVNV areas were analyzed by two masked reviewers and calculated as a percentage of total retinal area for each flatmount using Java-based imaging software (ImageJ version 1.46; National Institutes of Health, Bethesda, MD).
Cryosection Preparation and Immunofluorescence Staining and Quantification
Whole eye globes were fixed in 4% PFA containing 10 mM sodium orthovanadate for 10 minutes. Corneas and lenses were removed, and posterior eyecups were fixed for another 15 minutes in 4% PFA, then incubated in 30% sucrose/PBS at 48C overnight, and mounted in optimal cutting temperature compound (Tissue-Tek; Electron Microscopy Sciences, Hat-
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field, PA). Cryosections (12 lm) were cut sequentially and stained for immunofluorescence analysis. Cryosections were incubated with rabbit anti-phosphorylated VEGFR2 (p-VEGFR2 at Y951; Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 48C. After washes, sections were incubated with AlexaFluor 405 conjugated goat anti-rabbit second antibody for p-VEGFR2 and lectin for 1 hour. Sections stained with only secondary antibody and DAPI were controls. TUNEL staining was performed per instructions in the cell death detection kit (In Situ Cell Death Detection Kit, TMR red; Roche Diagnostics, Indianapolis, IN). DNase-treated sections were used as positive controls. Images were captured with confocal microscopy (Olympus IX81; Olympus Corp.). To determine the effects of knockdown on retinal VEGFR2 activation in captured images, semiquantitative assessment of the density of p-VEGFR2 was performed in sections of retina extending from the ganglion cell layer to lectin stained choroidal vessels depicting the RPE/choroid layer using Java-based imaging software (NIH). For p-VEGFR2 in retinal vessels, the density of p-VEGFR2 colabeling with lectin-stained ECs of the primary vascular plexus at the junctions between avascular retina and vascular retina was measured with the threshold function of the Java-based imaging software (NIH). TUNEL-positive cells colabeled with tetramethylrhodamine red (TMR red) and diamino-2-phenylindole (DAPI) were counted in retinal sections imaged at 34 magnification. Retinal thickness was measured from ganglion cell to ONL in DAPI-stained sections captured at 340 magnification using Java-based imaging software (NIH). In total, six sections taken at 60-lm intervals from three eyes of three pups in three litters were used for immunohistochemical analyses.
Retinal Protein Preparation and VEGF ELISA
Retinas were homogenized in modified radio-immunoprecipitation assay buffer containing 2 mM orthovanadate and protease inhibitors (Roche Diagnostics). Protein concentration was determined by bicinchocinic acid (BCA) protein assay (Pierce Biotechnology, Inc., Rockford, IL). Total retinal and serum VEGF concentration was measured using a commercial ELISA kit (Quantikine Rat VEGFA RRV00; R&D Systems, Minneapolis, MN) following manufacturer's instructions. Serum (50 lL) or 50 lg protein of retinal lysates was used for each sample, and samples were in duplicate.
Statistical Analysis
Significant differences between treatment groups were determined with ANOVA and Newman-Keuls multiple comparison test. For each test, a minimum value of P < 0.05 was considered statistically significant. Except where indicated otherwise, at least eight flat mounts, six samples for Western blot, and four samples for ELISA were analyzed. All samples were taken from different pups from at least three different litters. Results are mean 6 SD.
RESULTS
Generation and Knockdown Efficiency of Lentivector-Driven VEGF 164 -shRNA
We designed two different shRNAs for the rat VEGF 164 coding sequence (GenBank: AF260425) and cloned each into the lentivector pFmCD44.1 GW, which contains a CD44 promoter specific to Müller cells and drives a microRNA30 (miR-30)-based shRNA cassette and either RFP or GFP. To test knockdown efficiency of the designed shRNAs, lentivector plasmids containing either of the two shRNAs and an RFP tag or an empty vector were transfected into one of two HEK293 reporter cell lines that expressed either GFP-tagged rat VEGF 120 or VEGF 164 . Green fluorescent protein fluorescence intensity in RFP-expressed cells containing the shRNAs or empty vector was read using flow cytometry (Fig. 1A) . Neither VEGF164.shRNA-1 nor -2 had an effect on knockdown of VEGF 120 (Fig. 1B) (Fig. 1C) , whereas only VEGF 164 mRNA was reduced in the VEGF164.shRNA group. These results provide evidence that VEGF164.shRNA specifically knocked down VEGF 164 mRNA and not VEGF 120 .
Knockdown of VEGF 164 Reduced IVNV at P18 and P25
Images were taken before euthanasia using an applanation imaging system (Phoenix Research Laboratories, Inc.) to assess transduction of each of the three lentivectors that had been delivered as subretinal injections to P8 pup eyes. At P25, GFP fluorescence demonstrated that approximately 33% of the retina was transduced by each subretinal injection of lentivector shRNA and not with the PBS injection ( Fig. 2A) . Müller cell specificity was determined by colabeling of GFP and CRALBP in retinal cryosections (Fig. 2B) . To determine knockdown efficiency of VEGF in vivo, total retina lysates were analyzed for VEGF by ELISA. Compared with respective luciferase.shRNA controls at P18 and P25, retinal VEGF was significantly decreased by treatment with lentivector VEG-FA.shRNA or VEGF164.shRNA at both time points (Fig. 2C) .
VEGFA.shRNA and VEGF164.shRNA each significantly inhibited IVNV at P18 compared with luciferase.shRNA (Figs.  3A, 3B ). At P25, IVNV was significantly reduced in pup eyes treated with the luciferase.shRNA compared with those treated at P18. This was anticipated, because IVNV naturally regresses in the ROP model. At P25, VEGF164.shRNA significantly inhibited IVNV compared with VEGFA.shRNA, whereas VEG-FA.shRNA increased IVNV at P25 compared with P18. These findings suggest that VEGF164.shRNA, but not VEGFA.shRNA, was superior in maintaining inhibition of IVNV (Figs. 3A, 3B) , and that VEGFA.shRNA-treated eyes had recurrent IVNV. Neither VEGFA.shRNA nor VEGF164.shRNA had an effect on AVA at either P18 or P25, compared with luciferase.shRNA (Figs. 3A, 3C ).
VEGFR2 Activation in Retinal ECs
After Targeted VEGFA.shRNA or VEGF164.shRNA
To determine if targeted treatment with VEGFA.shRNA or VEGF164.shRNA inhibited total retinal VEGFR2 signaling, densitometry of p-VEGFR2 was measured from the ganglion cell layer to the RPE/choroid layer in cryosections colabeled with p-VEGFR2 and lectin (Figs. 4A, 4B) . To determine the effect of VEGFA.shRNA or VEGF164.shRNA on VEGFR2 activation in endothelial cells, lectin and p-VEGFR2 colabeling was analyzed with densitometry in the cryosections at the junctions between avascular and vascular retina in the inner plexus (Figs. 4A, 4C ). At P18, neither treatment significantly inhibited total retinal p-VEGFR2 density (Fig. 4B ) compared with luciferase.shRNA, but VEGFA.shRNA and VEGF164.shRNA each reduced colabeling of lectin and p-VEGFR2 in the vascular/avascular junction where IVNV developed (Fig. 4C) . At P25, there was increased p-VEGFR2 labeling in the retina in both VEGFA and VEGF164.shRNA sections compared with luciferase.shRNA (Fig. 4B) . There was also increased p-VEGFR2 colabeling with endothelial cells in VEGFA.shRNA-treated sections but not in VEGF164.shRNA-treated ones (Fig. 4C) .
VEGFA.shRNA and VEGF164.shRNA Effects on Retinal Survival, Serum VEGF, and Pup Growth VEGF is important to Müller cell health and neuroprotection. 13, 23 ,24 Therefore, we tested whether shRNAs to either 
Inhibition of Müller
VEGFA or VEGF 164 affected retinal cell survival at P18 or P25 by assessing TUNEL staining (Fig. 5A) . Compared with PBS, luciferase.shRNA increased TUNELþ cells at P18 but not at P25 (Fig. 5B) . Although we previously found VEGFA knockdown did not increase apoptosis in P18 retinal lysates, 12 sections from VEGFA.shRNA, but not VEGF164.shRNA treated eyes had significantly increased TUNELþ cells in both INL and ONL compared with luciferase.shRNA at P18. At P25, TUNELþ cells were significantly reduced compared with respective groups at P18, and there were no significant differences in TUNELþ cells among the groups at P25. Compared with PBS, luciferase.shR-NA treatment did not alter the thickness of the retina (data not shown), the INL (Fig. 5C ) or ONL (Fig. 5D) . However, eyes treated with the VEGFA.shRNA had significantly reduced ONL thickness compared with luciferase.shRNA at both P18 and P25 (Fig. 5D) . Compared with luciferase.shRNA, no differences in thickness of total retina at P18 or P25 (data not shown) or INL at P18 were detected after VEGFA.shRNA or VEGF164.shR-NA injections (Fig. 5C ). At P25, the INL was thicker in the VEGF164.shRNA group than the other groups (Fig. 5C ). Subretinal VEGFA.shRNA or VEGF164.shRNA did not affect body weight gain (Fig. 6A ) or serum VEGF (Fig. 6B ) compared with luciferase.shRNA at either time point.
DISCUSSION
We provide evidence that targeting Müller cells with an shRNA to one splice variant of VEGF, VEGF 164 , was safer and more effective at inhibiting and maintaining inhibition of IVNV than targeting all splice variants of VEGFA in a rat model representative of human ROP. We chose to target Müller cells, because we found that VEGF-splice variant mRNAs localized to cells in the INL corresponding to CRALBP-labeled Müller cells and that knockdown of VEGFA in Müller cells inhibited IVNV at the early time point, P18. 12 Previously, Bai et al. 25 found that Müller cell-expressed VEGF was important in causing IVNV by developing and testing a Müller cell conditional VEGF knockout in the mouse OIR model. Our study not only differs by testing long-term safety and comparing knockdown of a Müller cell-expressed splice variant-VEGF 164 -to knockdown of Müller cell-VEGFA, but also studies the rat OIR model, which FIGURE 5 . Analysis of retinal apoptosis and retinal morphological changes in the pups treated with lentivector-driven shRNAs in the rat ROP model. Images of TUNEL staining (A) and number of TUNEL (red) positive cells (B) in retinal DAPI (blue) stained cryosections from P18 and P25 pups treated with luc.shRNA, VEGFA.shRNA, and VEGF164.shRNA (**P < 0.01, ***P < 0.001 versus PBS at P18; † † †P < 0.001 versus luc.shRNA at P18). Quantification of the thickness of the INL (C) (***P < 0.001 versus PBS at P18; † †P < 0.01 versus luc.shRNA at P25) and the ONL (D) (***P < 0.001 versus luc.shRNA at P18; † †P < 0.001 versus luc.shRNA at P25) in DAPI-stained retinal cryosections from P18 and P25 OIR pups treated with luciferase.shRNA, VEGFA.shRNA, and VEGF164.shRNA. FIGURE 6. Lentivector-driven shRNAs treatment has no effect on pup growth and serum VEGF. Pup weight gains from P8 to P18 or P25 (A) and ELISA of serum VEGF in P18 or P25 pups (B) treated with luc.shRNA, VEGFA.shRNA, and VEGF164.shRNA in the rat ROP model. is a representative model of human ROP in places where oxygen is regulated. 26 Studies in human preterm infants show that IVNV can recur following anti-VEGF treatments. [27] [28] [29] Experimentally, broad inhibition of VEGF with an intravitreal neutralizing antibody led to upregulation of angiogenic compounds in association with recurrent IVNV. 9 We hypothesized that inhibition of all VEGF splice variants would affect both pathologic and physiologic processes and lead to cell death or compensatory upregulation of angiogenic pathways. Therefore, we targeted one splice variant of VEGF to inhibit pathologic angiogenesis and potentially preserve physiologic effects from VEGF. We chose VEGF 164 based on the finding that of the three rat splice variants of VEGFA (VEGF 120 , VEGF 164 , and VEGF 188 ), VEGF 164 was the most prevalent 10, 30 and unlike VEGF 120 or VEGF 188 , was increased in association with both older developmental age and the ROP model compared with RA. 10 We also found that VEGF 164 was upregulated by repeated fluctuations in oxygenation, whereas VEGF 120 was upregulated by hypoxia alone. 30 Physiologic events can be stimulated by hypoxia alone. 31 Also, evidence is accumulating that fluctuations in oxygenation are important in ROP. 32, 33 Others have reported VEGF 164 as the splice variant most likely to cause inflammation and abnormal angiogenesis.
14 For all these reasons, we compared the efficacy and safety of targeting Müller cell-VEGF 164 or -VEGFA with shRNAs in the rat model of ROP. We chose a lentivector because lentivirus is incorporated into the genome and provides a robust means to study VEGF knockdown longitudinally.
Although we found that targeting VEGF 164 with shRNA was more effective at maintaining inhibition of IVNV than targeting VEGFA, we cannot directly compare the two. The shRNA to VEGFA had greater knockdown in HEK164 reporter cell lines than did VEGF 164 -specific shRNA, which was selective to VEGF 164 and not VEGF 120 . Therefore, the dose effect of VEGF164.shRNA in Müller cells may account for some of the outcomes we found. For example, there was greater knockdown of VEGF in P18 retinal lysates from eyes treated with VEGFA.shRNA than with VEGF164.shRNA; but after a longer time for lentiviral transduction, VEGF164.shRNA treatment reduced VEGF in P25 retinal lysates similar to VEGFA.shRNA. VEGF 120 , which was not knocked down by VEGF164.shRNA, has soluble properties enabling it to move to other cells within the retina, and may have accounted for the lack of cell death and increased INL thickness noted in P25 sections from eyes treated with VEGF164.shRNA.
Based on densitometry of labeled retinal sections, knockdown of VEGF 164 or VEGFA had no effect on overall retinal VEGFR2 activation at P18; but at a later time point, both VEGFA.shRNA and VEGF164.shRNA each led to greater retinal p-VEGFR2. This suggests a compensatory increase in VEGFR2 activation. One explanation may be upregulation of VEGF in other cells in the retina. However, we did not find evidence of increased retinal VEGF at P25. The ELISA technique measures only unbound VEGF and may miss VEGF bound to VEGFR. 34 We previously found that Müller cell-VEGF activates endothelial cell VEGFR2. 12, 35 Therefore, to detect differences in p-VEGFR2 among the groups, we used a semiquantitative approach with densitometry of labeled retinal sections for endothelial cell p-VEGFR2. This method showed reduced p-VEGFR2 densitometry in ECs at P18, but increased p-VEGFR2 in ECs at P25 retinas that had been treated with the VEGFA.shRNA, not VEGF164.shRNA, and in association with an increase in IVNV at P25, suggesting compensatory signaling effects.
In a previous publication 12 and confirmed here, targeted knockdown of overexpressed VEGFA in Müller cells reduced IVNV at P18 without adversely affecting body weight gain or causing apoptosis measured as cleaved caspase-3 in retinal lysates. 9 Here, using TUNEL, we found VEGFA knockdown caused more cell death compared with luciferase.shRNA treatment. This may be because TUNEL does not discriminate apoptosis from necrosis and that the sensitivity in detecting a small group of cells undergoing apoptosis was insufficient using Western analysis of whole retinal lysates. At P25, there was no difference in TUNELþ cells, suggesting absence of ongoing cell death. However, VEGFA.shRNA also reduced ONL thickness at P25. Müller cells require VEGF for their own survival 13 and produce VEGF and other factors important to retinal neuronal survival, 28, 29 including photoreceptors whose nuclei reside in the ONL. Conditional knockout of Müller cells in a mouse model led to photoreceptor degeneration. 36 Future studies of the effects of long-term knockdown of Müller cell-VEGF such as through electrophysiology and spectral domain optical coherence tomography are warranted.
In summary, knockdown of splice variant, VEGF 164 , in Müller cells appears safer and more effective in inhibiting IVNV in the long-term than targeted knockdown of VEGFA, suggesting that maintaining the expression of some splice variants of VEGFA may improve survival of cells within the retina. Additional studies regarding potential compensatory signaling of Müller cells after VEGF inhibition and on long-term structure and function from knockdown of VEGFA or VEGF 164 are warranted. Effects of VEGF knockdown on endothelial effectors are also important to determine.
